EGFR and non-small cell lung carcinoma: With the discovery of the epidermal growth factor receptor (EGFR) gene and continuous research on tyrosine kinase inhibitor (TKI), treatment of advanced or metastatic patients with NSCLC has been greatly improved, and the overall survival has been extended [4, 5].